A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)
PHASE3CompletedINTERVENTIONAL
Enrollment
1,020
Participants
Timeline
Start Date
April 29, 2013
Primary Completion Date
March 25, 2014
Study Completion Date
March 25, 2014
Conditions
Rotavirus Gastroenteritis
Interventions
BIOLOGICAL
RotaTeq™ experimental formulation
BIOLOGICAL
RotaTeq™ existing formulation
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT01600092 - A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035) | Biotech Hunter | Biotech Hunter